Performance analysis of global sales of TOP14 prescription drugs in the first half of 2020

- Nov 19, 2020-

In the first half of 2020, the global sales of TOP14 prescription drugs ended at the beginning of last month. Basically all the semi-annual reports of multinational pharmaceutical companies have been released. The sales of each company’s main prescription drug products have slightly changed, mainly due to the novel corona virus in the second quarter of this year. The global impact of the epidemic has increased. The number of patients in hospitals in every country is decreasing. Non-emergency medical treatment and surgery are postponed, and the prescription period of chronic disease drugs has been lengthened. This has affected the sales of some products. According to statistics by Kentaro Nagae, an analyst in the Japanese pharmaceutical industry, 14 pharmaceutical companies had sales of more than US$10 billion in the first half of this year.

They are Roche, Novartis,Pfizer,Janssen,BMSBristol Myers Squibb,Merck, AbbVie, Sanofi, GSK(GlaxoSmithKline),Takeda, AstraZeneca,Amgen, Eli Lilly, Gilead Sciences.